Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation
Authors:
- Erin CooneyECErin Cooney
- Carmella van de VenCVCarmella van de Ven
- Mitchell S. CairoMCMitchell S. Cairo
- 18 May 2007
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (2) , 325-330
Abstract
Background: Invasive mold infections (IMI) are a leading cause of infectious mortality in allogeneic stem cell transplant (AlloSCT) recipients. Fluconazole, the current standard for fungal prophylaxis, is ineffective against molds. We initiated a pilot study to determine the safety and activity of prophylactic liposomal amphotericin B (AMB) in preventing IMI in pediatric and adolescent AlloSCT recipients during the first 100 days.Procedure: Fifty‐one patients (57 AlloSCT) were given AMB (3 mg/kg/day) intravenously, day 0–100. Median age 6 years, 32 males, 19 females. Donors: 33 unrelated and 2 related cord blood, 13 related and 1 unrelated peripheral blood stem cell and 8 related bone marrow (BM); 30 received myeloablative and 27 reduced intensity conditioning. Graft‐versus‐host disease (GVHD) prophylaxis comprised tacrolimus and mycophenolate mofetil.Results: Median follow‐up is 557 days. AMB was generally well tolerated. The probability of developing ≥grade II acute GVHD and extensive chronic GVHD was 45% and 7%, respectively. Estimated 1‐year OS is 62.4% for all patients with 78.8% and 26.7% for average‐risk and poor‐risk, respectively. The incidence of IMI was 0%.Conclusions: These results suggest prophylactic AMB is tolerable and may prevent IMI, especially Aspergillus, during the first 100 days post AlloSCT in pediatric and adolescent patients. A randomized study is needed to determine the efficacy of this approach. Pediatr Blood Cancer 2008;50:325–330.Keywords
This publication has 30 references indexed in Scilit:
- High-Dose Weekly AmBisome Antifungal Prophylaxis in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Pharmacokinetic StudyTransplantation and Cellular Therapy, 2006
- The Hepatotoxicity of Antifungal Medications in Bone Marrow Transplant RecipientsClinical Infectious Diseases, 2005
- A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipientsBone Marrow Transplantation, 2004
- Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimenBone Marrow Transplantation, 2003
- Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during inductionCancer, 2003
- Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?Bone Marrow Transplantation, 2002
- Outcome of second hematopoietic cell transplantation in Hurler syndromeBone Marrow Transplantation, 2002
- Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantationBone Marrow Transplantation, 1999
- Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled studyBone Marrow Transplantation, 1999
- Incidence and risk factors for invasive fungal infections in allogeneic BMT recipientsBone Marrow Transplantation, 1997